Cannabis-based products are more likely to be used by multiple sclerosis (MS) patients with higher levels of disability and pain than those with lesser disability or pain, according to a study of findings in Spain and France. This “may encourage health authorities to consider relaxing the barriers to cannabis use for…

The Kanabo Group has established what it claims is the U.K.’s first online medical cannabis clinic to help people with multiple sclerosis and other conditions manage chronic pain. Called Treat It, the clinic is expected to help those whose conventional pharmaceutical medicines are ineffective or those…

Sativex (nabiximols), a cannabis-based oral spray approved in the U.K. to ease spasticity — or muscle stiffness and spasms — in adults with multiple sclerosis (MS), remains unavailable to many patients there, according to a report by the MS Society UK. Sativex is the only licensed…

Medical cannabis made by Panaxia Labs Israel will be marketed and distributed in Greece by Leriva Group, under a recent agreement between the two companies and pending a marketing authorization in the country. The product will be sold under the brand name Panaxir. The companies expect to start…

A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U.K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions. NICE also recommended against prescribing Sativex as a treatment for…

Medical cannabis products, jointly developed by GB Sciences Louisiana (GBSL) and the Louisiana State University Agricultural Center‘s (LSU AgCenter) Therapeutic Cannabis Program, are now available for purchase by qualified patients with illnesses that include multiple sclerosis (MS) at nine state-licensed pharmacies. The decision, announced by the Louisiana Department…

Stanford Researchers Open Medical Cannabis Company with Oral Therapy for MS Pain, Spasticity as Initial Goal Let’s be clear up front. There’s no indication that you’ll be able to buy a cannabis pill from this company anytime soon — or ever. The company’s website says that testing…

Most general practitioners in Australia favor prescribing medical cannabis to treat spasticity in multiple sclerosis (MS) or pain in select other diseases, but are not allowed to under current laws and say they know little about its use, according to results of a national survey. A study based on its…

Medical cannabis is a safe and effective treatment for pain relief and should be integrated into current clinical practice, according to a new evidence overview. Benefits also include reduced spasticity in multiple sclerosis patients. The overview, titled “Special Issue: Cannabis in Medicine,” was published in the…

More studies are showing that medical cannabis can alleviate symptoms of multiple sclerosis (MS), according to a company that helps patients, doctors and others understand genetic conditions better. The observation came in GeneFo’s 2018 Guide to Clinical Effects of Medical Cannabis. Some research has suggested that cannabis strains containing…

Registered patients in Canada can now purchase CanniMed Topical Cream, a product with medical cannabis oil designed to provide fast-acting relief for patients with multiple sclerosis (MS) and other conditions associated with pain and inflammation. The product is the result of a collaboration between Canada-based CanniMed Therapeutics and Avaria…

Cannabis Science has created a website called iCannabinoid that it hopes will become the premier online source of medical cannabis news and information. It is seeking feedback on the site so it can tweak it as need be. It hopes to hear from  patients, doctors, patient advocates, parents, researchers, government and…

Medical cannabis was found to safely and significantly reduce chronic pain in older patients with multiple sclerosis (MS) and a wide range of other conditions, researchers in Israel report. Led by scientists at Ben-Gurion University of the Negev (BGU) and the Cannabis Clinical Research Institute at Soroka University Medical…

Ninety-five percent of multiple sclerosis (MS) patients believe medical marijuana should be a treatment option, according to a GeneFo online survey. The survey also showed that almost 73 percent had tried it, even though about half said they hadn’t received information from a doctor about its benefits and risks. A National…

Most Irish general practitioners (GPs) are against decriminalizing cannabis use, but many, especially those over age 50, say it can be useful for treating multiple sclerosis (MS) and other medical conditions, according to a recent survey. The results are detailed in the study, “Irish general practitioner attitudes toward decriminalisation…

CannaCure Florida, a patient-focused producer of medical cannabis and related products, will host physicians and medical professionals for a peer-to-peer medical cannabis educational conference Nov. 18 in Tampa to provide guidance for incorporating medical cannabis into traditional medical practices. The event will be held 9 a.m. to 4:30 p.m. at the Cuban…

Abide Therapeutics announced that Celgene has opted to obtain the rights, outside of the United States, to ABX-1431, Abide’s endocannabinoid system modulator being developed to treat neurological diseases, including multiple sclerosis (MS), by reproducing within the body the physical benefits (minus the psychotropic effects) of cannabis. ABX-1431 is an…

Montel Williams, a Naval Academy graduate diagnosed with multiple sclerosis (MS) in 1999 , recently announced the launch of a line of high-quality medical cannabis products under the brand name LenitivLabs by Lenitiv Scientific. The former television host and wellness advocate has been particularly vocal when it comes to support the use of medical…

Medical cannabis is subject to laws relating to the growing, possession, transport, and use of marijuana. These vary from country to country and, in the United States, from state to state. There are also differences between marijuana for general and recreational use and for the same product for medical use.

MedChew Rx, by AXIM Biotechnology, the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is moving into clinical testing. If all goes well, the company plans for a global release date of 2017. Medical cannabis is believed to have considerable promise as a therapy for…

AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testing a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money,…